The BH3-only protein Noxa is stimulated during apoptosis of chronic lymphocytic leukemia cells triggered by M2YN, a new plant-derived extract.
暂无分享,去创建一个
Christian Billard | I. Bombarda | Massoud Mirshahi | Jean-Pierre Marie | Isabelle Bombarda | Murhaf Zaher | Yusuf Nuraliev | Mijgana Sharifova | J. Marie | M. Mirshahi | C. Billard | Yusuf Nuraliev | M. Zaher | M. Sharifova
[1] Di Chen,et al. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. , 2005, Biochemical pharmacology.
[2] J. Kolb,et al. Noxa upregulation is associated with apoptosis of chronic lymphocytic leukemia cells induced by hyperforin but not flavopiridol , 2009, Leukemia.
[3] T. Riss,et al. Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format. , 2009, Analytical biochemistry.
[4] M. Grever,et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.
[5] M. Keating,et al. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. , 2008, Blood.
[6] C. Scott,et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.
[7] M. Caligiuri,et al. Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity , 2007, Clinical Cancer Research.
[8] M. Rothley,et al. Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor‐induced lymphangiogenesis in vivo , 2009, International journal of cancer.
[9] S. Malek,et al. Chronic Lymphocytic Leukemia , 2019, Methods in Molecular Biology.
[10] Y. Naït-Si,et al. Effect of eluent pH on the HPLC-UV analysis of hyperforin from St. John's Wort (Hypericum perforatum L.). , 2006, Phytochemical analysis : PCA.
[11] G. Cohen,et al. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa , 2007, Leukemia.
[12] P. Hersey,et al. Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiol-induced apoptosis of human melanoma cells , 2006, Anti-cancer drugs.
[13] J. Byrd,et al. Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemia , 2006, Cancer.
[14] J. Kolb,et al. Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. , 2003, Current drug targets. Cardiovascular & haematological disorders.
[15] John Calvin Reed,et al. Protein Kinase Inhibitors Flavopiridol and 7-hydroxy-staurosporine Down-regulate Antiapoptosis Proteins in B-cell Chronic Lymphocytic Leukemia , 2022 .
[16] Laurent Bélec,et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis , 2007, Proceedings of the National Academy of Sciences.
[17] L. Pleyer,et al. Molecular and cellular mechanisms of CLL: novel therapeutic approaches , 2009, Nature Reviews Clinical Oncology.
[18] S. Aiyar,et al. TMS, a chemically modified herbal derivative of Resveratrol, induces cell death by targeting Bax , 2010, Breast Cancer Research and Treatment.
[19] M. Blagosklonny. Flavopiridol, An Inhibitor of Transcription: Implications, Problems and Solutions , 2004, Cell cycle.
[20] M. Grever,et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. , 1998, Blood.
[21] Derek A. West,et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. , 2009, Blood.
[22] John Calvin Reed,et al. Triterpenoids Display Single Agent Anti-tumor Activity in a Transgenic Mouse Model of Chronic Lymphocytic Leukemia and Small B Cell Lymphoma , 2007, PloS one.
[23] W. Plunkett,et al. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. , 2005, Blood.
[24] Chun-ching Lin,et al. Isoliquiritigenin induces apoptosis and cell cycle arrest through p53-dependent pathway in Hep G2 cells. , 2005, Life sciences.
[25] G. Packham,et al. Bodyguards and assassins: Bcl‐2 family proteins and apoptosis control in chronic lymphocytic leukaemia , 2005, Immunology.
[26] A. Faussat,et al. 4-arylcoumarin analogues of combretastatins stimulate apoptosis of leukemic cells from chronic lymphocytic leukemia patients. , 2008, Experimental hematology.
[27] R. Mohammad,et al. Analysis of resveratrol‐induced apoptosis in human B‐cell chronic leukaemia , 2002, British journal of haematology.
[28] M. Grever,et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. , 2005, Leukemia research.
[29] Lin Chen,et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. , 2005, Genes & development.
[30] S. Parodi,et al. Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic , 2009, Cancer biology & therapy.
[31] Thomas S. Lin,et al. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. , 2009, Blood.
[32] A. Ballestrero,et al. Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. , 2005, Blood.
[33] C. Peschel,et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells , 2004, Leukemia.
[34] F. Ajchenbaum‐Cymbalista,et al. Flavopiridol downregulates the expression of both the inducible NO synthase and p27kip1 in malignant cells from B-cell chronic lymphocytic leukemia , 2003, Leukemia.
[35] H. Xin,et al. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. , 2006, Cancer research.
[36] S. Shankar,et al. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. , 2007, Frontiers in bioscience : a journal and virtual library.
[37] B. Cheson,et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. , 2009, Blood.
[38] M. Keating,et al. Chemoimmunotherapy of chronic lymphocytic leukemia. , 2007, Best practice & research. Clinical haematology.
[39] F. Ajchenbaum‐Cymbalista,et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. , 2004, Blood.
[40] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[41] Liang Xu,et al. Natural Proteasome Inhibitor Celastrol Suppresses Androgen-Independent Prostate Cancer Progression by Modulating Apoptotic Proteins and NF-kappaB , 2010, PloS one.
[42] A. Faussat,et al. Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia , 2006, Leukemia.
[43] Lisa S. Chen,et al. Mcl-1: the 1 in CLL. , 2008, Blood.
[44] Annelieke Jaspers,et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. , 2007, Blood.
[45] M. Hendrix,et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. , 2005, Cancer research.